RADAR for Pharma See the horizon. Find your way.

Evidence-grounded forecasts before the next pharma decision.

Portfolio selection, trial-design tradeoffs, market pressure, and deal structure from the same model output your team can audit.

Trial Design Optimizer

Non-small cell lung cancer, Phase III

47.7% benchmark
47.7%Phase III to NDA/BLA filing
43.9%Implied approval from Phase III
100Active Phase III lung-cancer trials
60%Estimated peak-share erosion
47.7% phase benchmark Open-label, unblinded, N=1,000 54.1% RCT, unblinded, N=1,000 53.1% Open-label, blinded, N=1,000 52.5% RCT, blinded, N=1,000 51.5% Open-label, unblinded, N=500 50.4% RCT, unblinded, N=500 49.3%

Development Benchmarks

Oncology transition ladder

Phase I
48.8%
Phase II
24.6%
Phase III
47.7%
NDA/BLA
92.0%

Stochastic Forecast

Demo oncology asset NPV distribution

19.4% positive
-$188MP10 NPV
-$33MP50 NPV
$57MMean NPV
$532MP90 NPV

Deal Strategy

Buyer range and negotiation guardrails

$472MAuction price estimate
$732MTop acquirer WTP
$145MSeller walk-away
153Tracked assumptions